# AUDITED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2018 FOR ONYX SCIENTIFIC LIMITED



## CONTENTS OF THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2018

|                                   | • | Page |
|-----------------------------------|---|------|
| Company Information               |   | 1    |
| Balance Sheet                     |   | 2    |
| Notes to the Financial Statements | , | 3    |

## COMPANY INFORMATION FOR THE YEAR ENDED 31 MARCH 2018

**DIRECTORS:** 

Mrs D Bowser

Dr D J Londesbrough

N V Lane P Godha

**REGISTERED OFFICE:** 

Units 97-98 Silverbriar

Sunderland Enterprise Park East

Sunderland Tyne and Wear SR5 2TQ

**REGISTERED NUMBER:** 

03947634 (England and Wales)

**AUDITORS:** 

Leesing Marrison Lee Limited

**Chartered Certified Accountants** 

Statutory Auditors 46 Main Street Mexborough South Yorkshire S64 9DU

**BANKERS:** 

**HSBC** 

33 Park Row

Leeds ·

West Yorkshire

LS1 1LD

## **ONYX SCIENTIFIC LIMITED (REGISTERED NUMBER: 03947634)**

#### BALANCE SHEET 31 MARCH 2018

|                                     |        | 2018       | :                    | 2017  |                                       |
|-------------------------------------|--------|------------|----------------------|---|---------------------------------------|
|                                     | Notes  | £          | £                    | £   | £                                     |
| FIXED ASSETS                        |        |            | 4 004 400            |   | 050 736                               |
| Tangible assets Investments         | 4<br>5 |            | 1,094,192<br>720,935 | K   | 858,726                               |
| Tilvesurierics                      | 3      |            | <del></del>          |   |                                       |
|                                     |        |            | 1,815,127            | 5   | 858,726                               |
| CURRENT ASSETS                      |        |            |                      |   |                                       |
| Stocks                              |        | 609,767    |                      | 386,739   |                                       |
| Debtors                             | 6      | 1,081,610  |                      | 2,150,747                                       |                                       |
| Cash at bank and in hand            |        | 720,158    |                      | 1,401,400                                       |                                       |
|                                     |        | 2,411,535  |                      | 3,938,886                                       | · · · · · · · · · · · · · · · · · · · |
| CREDITORS                           |        | 2, 111,555 |                      | 3/330/000                                       |                                       |
| Amounts falling due within one year | 7      | 1,091,009  |                      | 995,944   |                                       |
| NET CURRENT ASSETS                  |        |            | 1,320,526            |   | 2,942,942                             |
| TOTAL ASSETS LESS CURRENT           |        |            |                      |   |                                       |
| LIABILITIES                         |        |            | 3,135,653            |   | 3,801,668                             |
| PROVISIONS FOR LIABILITIES          | 9      |            | 104,827              |   | 218,270                               |
| NET ASSETS                          |        |            | 3,030,826            |   | 3,583,398                             |
|                                     |        |            |                      | -   |                                       |
| CAPITAL AND RESERVES                |        |            |                      |   | 5.0                                   |
| Called up share capital             | 10     |            | 368,122              |   | 368,122                               |
| Share premium                       |        |            | 12,358               | •   | 12,358                                |
| Retained earnings                   |        |            | 2,650,346            | ہے۔ ہے۔ اور | 3,202,918                             |
| CHARGINAL DEDGI FILINGS             |        |            | 2 020 026            |   | 2 502 200                             |
| SHAREHOLDERS' FUNDS                 |        |            | 3,030,826            |   | 3,583,398                             |
|                                     |        |            |                      | <u> </u>  |                                       |

The financial statements have been prepared and delivered in accordance with the provisions of Part 15 of the Companies Act 2006 relating to small companies.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

N V Lane - Director

Or D J Londesbrøugh - Director

Mrs D Bowser - Director

The notes form part of these financial statements

#### NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2018

#### 1. STATUTORY INFORMATION

Onyx Scientific Limited is a private company, limited by shares, registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

#### 2. **ACCOUNTING POLICIES**

#### Basis of preparing the financial statements

These financial statements have been prepared in accordance with the provisions of Section 1A "Small Entities" of Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

#### Turnover

Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

#### Tangible fixed assets

Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life

Improvements to property

- 10% on cost

Plant and machinery

- at varying rates on cost and at variable rates on reducing balance

Fixtures and fittings

- 25% on reducing balance

Computer equipment

- 25% on reducing balance

#### **Investments in associates**

Investments in associate undertakings are recognised at cost.

#### Research and development

Expenditure on research and development is written off in the year in which it is incurred.

#### Foreign currencies

Assets and liabilities in foreign currencies are translated into sterling at the rates of exchange ruling at the balance sheet date. Transactions in foreign currencies are translated into sterling at the rate of exchange ruling at the date of transaction. Exchange differences are taken into account in arriving at the operating result.

#### Hire purchase and leasing commitments

Rentals paid under operating leases are charged to profit or loss on a straight line basis over the period of the lease.

#### Pension costs and other post-retirement benefits

The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

#### Grants

Grants relating to revenue items are credited to the Profit and Loss Account in the same accounting period as the expenditure to which the grant relates. Grants in respect of Capital items are credited to to the Profit and Loss Account over the same period as the asset to which the grant relates is written off.

#### Stocks

Stocks and work in progress are valued at cost, determined on a first in first out basis, after making the appropriate allowance tor obsolete and slow moving items.

Cost of work in progress consists of direct costs and an appropriate proportion of fixed and variable overheads.

#### **Deferred tax**

Deferred tax is recognised in respect of all material timing differences that have originated but have not reversed at the balance sheet date.

#### 3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 52 (2017 - 52)

# NOTES TO THE FINANCIAL STATEMENTS - continued FOR THE YEAR ENDED 31 MARCH 2018

#### 4. TANGIBLE FIXED ASSETS

|                        | Improvements |             | Fixtures           |           |           |
|------------------------|--------------|-------------|--------------------|-----------|-----------|
|                        | to           | Plant and   | , and              | Computer  |           |
|                        | property     | machinery   | fittings           | equipment | Totals    |
|                        | £            | , , £       | £                  | · £       | £         |
| COST                   |              |             | ,                  |           | •         |
| At 1 April 2017        | 981,483      | 3,177,501   | 41,008             | 122,726   | 4,322,718 |
| Additions              | 61,616       | 371,089     | 4,365              | 9,055     | 446,125   |
| Disposals              | <del>.</del> | -           |                    | (49,841)  | (49,841)  |
| At 31 March 2018       | 1,043,099    | 3,548,590   | 45,373             | 81,940    | 4,719,002 |
| DEPRECIATION           |              |             | i                  |           |           |
| At 1 April 2017        | 805,233      | 2,536,036   | 33,241             | 89,482    | 3,463,992 |
| Charge for year        | 38,669       | 156,856     | <sup>'</sup> 3,188 | 10,084    | 208,797   |
| Eliminated on disposal | <u>-</u>     | -           | *                  | (47,979)  | (47,979)  |
| At 31 March 2018       | 843,902      | 2,692,892   | 36,429             | 51,587    | 3,624,810 |
| NET BOOK VALUE         |              |             | ,                  |           |           |
| At 31 March 2018       | 199,197      | 855,698     | 8,944              | 30,353    | 1,094,192 |
| At 31 March 2017       | 176,250      | 641,465     | 7,767              | 33,244    | 858,726   |
|                        |              | <del></del> | :                  |           |           |

#### 5. FIXED ASSET INVESTMENTS

|                                    |                                       | in<br>associate<br>£ |
|------------------------------------|---------------------------------------|----------------------|
| COST . Additions                   | · · · · · · · · · · · · · · · · · · · | 720,935              |
| At 31 March 2018                   | · •                                   | 720,935              |
| NET BOOK VALUE<br>At 31 March 2018 | ·<br>·                                | 720,935              |

During the year the Company has acquired 10% common stock of Pisigah Laboratories Inc. (PIsgah) based out of North Carolina, USA. Pisgah was originally founded in the year 1981 as a contract manufacturer and developer of active pharmaceutical ingredients (APIs) and intermediates and has been a chemistry solutions provider for over three decades. This acquisition will help the Company to establish its foothold in the US market (including but not limited to) in the field of research / small volume APIs and intermediates manufacturing. Pisgah will continue to operate out of its North Carolina manufacturing facility under the Pisgah trade name.

#### 6. **DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR**

|                                    | 3          | £             |
|------------------------------------|------------|---------------|
| Trade debtors                      | 97         | 8,444 669,930 |
| Amounts owed by group undertakings |            | - 942,824     |
| Other debtors                      | <u>:</u> 2 | 8,539 28,539  |
| Tax                                | <u>;</u>   | - 434,205     |
| Prepayments                        | 7          | 4,627 75,249  |
|                                    | 1,08       | 2,150,747     |
|                                    |            |               |

2017

2018

Interest

# NOTES TO THE FINANCIAL STATEMENTS - continued FOR THE YEAR ENDED 31 MARCH 2018

| 7. | CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR                   | •                  |           |             |
|----|--|--------------------|-----------|-------------|
|    |  |                    | 2018      | 2017        |
|    |  | 1                  | £         | £           |
|    | Trade creditors  | •                  | 287,913   | 375,556     |
|    | Corporation Tax  |                    | 150,200   | · -         |
|    | Social security and other taxes                                  |                    | 46,600    | 44,988      |
|    | VAT  |                    | 60,685    | 53,543      |
|    | Other creditors  | Ş                  | 147,640   | 405         |
|    | Accrued expenses   | \$                 | 397,971   | 515,331     |
|    | Deferred government grants                                       | c<br>c             |           | 6,121       |
|    |  |                    | 1,091,009 | 995,944     |
|    |  | ;                  |           |             |
| 8. | LEASING AGREEMENTS   |                    |           |             |
|    | Minimum lease payments under non-cancellable operating leases fa | ill due as follows | S:        |             |
|    |  |                    | 2018      | 2017        |
|    | •  | :                  | £         | £           |
|    | Within one year  | ·                  | 2,435     | 3,009       |
|    | Between one and five years                                       | :                  | 151,250   | 112,969     |
|    |  | t .                |           |             |
|    |  | :                  | 153,685   | 115,978     |
|    |  | · •                | •         |             |
| 9. | PROVISIONS FOR LIABILITIES                                       | 4                  |           |             |
| э. | PROVISIONS FOR LIABILITIES                                       | 3                  | 2018      | 2017        |
|    |  | 3                  | £         | £           |
|    | Deferred tax   | 1                  | 104,827   | 218,270     |
|    | Deferred dix   |                    | =====     | =====       |
|    |  | •                  |           | Deferred    |
|    |  |                    |           | tax         |
|    |  |                    |           | £           |
|    | Balance at 1 April 2017  | •                  |           | 218,270     |
|    | Accelerated capital allowances                                   | •                  |           | 15,418      |
|    | Other  |                    |           | (124,155)   |
|    | Rate change  | •                  |           | ` (4,706)   |
|    |  | •                  |           | <del></del> |
|    | Balance at 31 March 2018   |                    |           | 104,827     |
|    |  |                    |           | =           |
|    |  |                    |           |             |

The other deferred tax credit for the year of £124,155 is the reversal of the provision made in 2017 for the corporation tax payable on the Research & Development Expenditure Credit.

#### 10. CALLED UP SHARE CAPITAL

| Allotted, issu | ed and fully paid: | •        |         |         |
|----------------|--------------------|----------|---------|---------|
| Number:        | Class:             | Nomiุกลl | 2018    | 2017    |
|                |                    | valıje:  | £       | £       |
| 368,122        | Ordinary           | £₫       | 368,122 | 368,122 |
|                |                    |          |         |         |

## 11. DISCLOSURE UNDER SECTION 444(5B) OF THE COMPANIES ACT 2006

The Report of the Auditors was unqualified.

Robert Tippett FCCA (Senior Statutory Auditor) for and on behalf of Leesing Marrison Lee Limited

Robati Tipett

# NOTES TO THE FINANCIAL STATEMENTS - continued FOR THE YEAR ENDED 31 MARCH 2018

#### 12. CAPITAL COMMITMENTS

| i e e                                  | - ' | . 2018 | 2017   |
|--|-----|--------|--------|
| •                                      | 7   | £      | £      |
| Contracted but not provided for in the | •   |        |        |
| financial statements                   | 4   | 67,197 | 70,626 |
|  | •   |        |        |

#### 13. RELATED PARTY DISCLOSURES

The entire share capital of the company is owned by Ipca Laboratories (UK) Limited.

Ipca Laboratories (UK) Limited

During the year to 31 March 2018, Ipca Laboratories (UK) Limited was paid a dividend amounting to £1,964,463 (2017 management fee: £360,000, dividend £368,122).

At the balance sheet date, an amount of £nil (2017: £4,000) was due by the company.. At the same date, there is also an inter-company loan balance of £nil (2015: £942,823) due to the company.

## 14. APB ETHICAL STANDARD - PROVISIONS AVAILABLE FOR SMALL ENTITIES

In common with many other businesses of our size and nature we use our auditors to prepare and submit returns to the tax authorities, assist with the preparation of the financial statements and payroll services.

#### 15. ULTIMATE CONTROLLING PARTY

The company is a wholly owned subsidiary of Ipca Laboratories (UK) Limited, which is a wholly owned subsidiary of Ipca Laboratories Limited, a company listed on the Bombay stock exchange and National stock exchange of India.